Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

BD Cheson; N Chua; J Mayer; G Dueck; M Trneny; K Bouabdallah; N Fowler; V Delwail; O Press; G Salles; JG Gribben; A Lennard; Elly Lugtenburg; G Fingerle-Rowson; F Mattiello; A Knapp; L H Sehn

doi:10.1200/jco.2017.76.3656

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

BD Cheson, N Chua, J Mayer, G Dueck, M Trneny, K Bouabdallah, N Fowler, V Delwail, O Press, G Salles, JG Gribben, A Lennard, Elly Lugtenburg, G Fingerle-Rowson, F Mattiello, A Knapp, L H Sehn

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

106 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2259-+
Journal	Journal of Clinical Oncology
Volume	36
Issue number	22
DOIs	https://doi.org/10.1200/jco.2017.76.3656
Publication status	Published - 2018

Research programs

EMC OR-01

Access to Document

10.1200/jco.2017.76.3656

http://hdl.handle.net/1765/114457

Cite this

Cheson, BD., Chua, N., Mayer, J., Dueck, G., Trneny, M., Bouabdallah, K., Fowler, N., Delwail, V., Press, O., Salles, G., Gribben, JG., Lennard, A., Lugtenburg, E., Fingerle-Rowson, G., Mattiello, F., Knapp, A., & Sehn, L. H. (2018). Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. Journal of Clinical Oncology, 36(22), 2259-+. https://doi.org/10.1200/jco.2017.76.3656

@article{b0c0d5d7e4e346488796792e96b7c645,

title = "Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study",

author = "BD Cheson and N Chua and J Mayer and G Dueck and M Trneny and K Bouabdallah and N Fowler and V Delwail and O Press and G Salles and JG Gribben and A Lennard and Elly Lugtenburg and G Fingerle-Rowson and F Mattiello and A Knapp and Sehn, {L H}",

year = "2018",

doi = "10.1200/jco.2017.76.3656",

language = "Undefined/Unknown",

volume = "36",

pages = "2259--+",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "22",

}

Cheson, BD, Chua, N, Mayer, J, Dueck, G, Trneny, M, Bouabdallah, K, Fowler, N, Delwail, V, Press, O, Salles, G, Gribben, JG, Lennard, A, Lugtenburg, E, Fingerle-Rowson, G, Mattiello, F, Knapp, A & Sehn, LH 2018, 'Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study', Journal of Clinical Oncology, vol. 36, no. 22, pp. 2259-+. https://doi.org/10.1200/jco.2017.76.3656

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. / Cheson, BD; Chua, N; Mayer, J et al.
In: Journal of Clinical Oncology, Vol. 36, No. 22, 2018, p. 2259-+.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

AU - Cheson, BD

AU - Chua, N

AU - Mayer, J

AU - Dueck, G

AU - Trneny, M

AU - Bouabdallah, K

AU - Fowler, N

AU - Delwail, V

AU - Press, O

AU - Salles, G

AU - Gribben, JG

AU - Lennard, A

AU - Lugtenburg, Elly

AU - Fingerle-Rowson, G

AU - Mattiello, F

AU - Knapp, A

AU - Sehn, L H

PY - 2018

Y1 - 2018

U2 - 10.1200/jco.2017.76.3656

DO - 10.1200/jco.2017.76.3656

M3 - Article

SN - 0732-183X

VL - 36

SP - 2259-+

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 22

ER -